Isomorphic Labs, the Alphabet-backed AI biotech focused on drug design, closed a $2.1 billion Series B round to scale its unified drug discovery engine. Thrive Capital led the round with participation from Alphabet and GV, alongside other investors including MGX, Temasek and CapitalG, supporting plans to expand IsoDDE and push earlier candidates toward the clinic.